Sofiva Genomics Co., Ltd. (6615) AI Stock Analysis

Sofiva Genomics Co., Ltd.

(TPEx:6615)

Select Model

Rating:51Neutral

Price Target:TWD 33.00▲(1.54% Upside)

Action:initiatedcoverage

Date:11/09/26

Financial performance, bolstered by a solid balance sheet, is the primary positive factor, while subdued technical indicators and unfavorable valuation metrics weigh on the score.

Positive Factors

Conservative Balance SheetLow leverage and stable equity give Sofiva a meaningful financial cushion while earnings are weak. Debt-to-equity improved to very low levels in 2025, preserving flexibility to fund laboratory operations, absorb volatility, and pursue opportunities without heavy financing pressure.

Negative Factors

Multi-Year Revenue DeclineA multi-year revenue contraction signals weakening commercial momentum rather than a single-period fluctuation. Sustained top-line pressure can reduce operating leverage, constrain investment in testing capabilities, and make it harder for Sofiva to rebuild durable earnings growth over the coming quarters.

Sofiva Genomics Co., Ltd. (6615) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 708.26M
Dividend Yield: 0.93%
Average Volume (3M): 12.13K
Price to Earnings (P/E): 49.2
Beta (1Y): 0.21
Revenue Growth: -6.67%
EPS Growth: ―
Country: TW
Employees: 15
Sector: General
Sector Strength: 55
Industry: Medical - Diagnostics & Research

Sofiva Genomics Co., Ltd. Business Overview & Revenue Model

Company Description

Sofiva Genomics Co.,Ltd., established in 2012 and based in Taipei, Taiwan, offers a comprehensive range of genetic testing services to both domestic and international clients. The company's diverse diagnostic solutions are designed to support expecta...

Sofiva Genomics Co., Ltd. Financial Statement Overview

Summary

The balance sheet remains a key strength with low debt-to-equity of 0.06, though revenue declines and margin compression have led to a net loss; improving free cash flow provides partial offset.

Income Statement

32Negative

Balance Sheet

88Very Positive

Cash Flow

58Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	379.21M	385.71M	453.31M	466.80M	495.77M	508.42M
Gross Profit	100.71M	99.13M	135.66M	129.91M	148.99M	176.81M
EBITDA	52.80M	7.87M	66.34M	27.86M	46.58M	77.19M
Net Income	14.73M	-9.36M	18.43M	11.53M	42.78M	56.98M
Balance Sheet
Total Assets	735.62M	724.35M	768.08M	767.14M	807.56M	822.30M
Cash, Cash Equivalents and Short-Term Investments	131.52M	124.71M	146.18M	140.03M	170.96M	245.19M
Total Debt	38.30M	35.53M	53.38M	63.59M	74.67M	90.14M
Total Liabilities	87.74M	95.91M	123.68M	148.77M	180.24M	197.86M
Stockholders Equity	648.13M	628.13M	644.04M	618.14M	626.92M	624.23M
Cash Flow
Free Cash Flow	27.40M	7.20M	10.57M	-859.00K	-18.56M	67.42M
Operating Cash Flow	30.38M	15.36M	34.69M	23.70M	17.14M	80.07M
Investing Cash Flow	-2.79M	-14.44M	-10.66M	-9.99M	-53.48M	-10.03M
Financing Cash Flow	-10.79M	-22.28M	-8.57M	-36.67M	-58.65M	-44.19M

Sofiva Genomics Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6615 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:6615	51Neutral	TWD 696.39M	49.24	―	0.93%	-6.67%	―

* General Sector Average

Performance Comparison

TW:6615 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6615	Sofiva Genomics Co., Ltd.	32.50	1.90	6.21%
TW:4117	General Biologicals Corp.	7.41	-4.79	-39.26%
TW:4732	Naturewise Biotech & Medicals Corporation	15.20	-4.90	-24.38%
TW:6493	TTBIO CORP.	28.80	-0.30	-1.03%
TW:6572	PlexBio Co., Ltd.	6.28	-3.12	-33.19%
TW:6939	TFBS Bioscience, Inc.	18.90	-4.60	-19.57%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Sofiva Genomics Co., Ltd. AI Stock Analysis